Core Insights - The core viewpoint of the article highlights the strong performance of Bluestar Medical in the cardiovascular sector, showcasing significant revenue growth and product innovation [1] Business Performance - The cardiovascular division achieved revenue exceeding 1 billion yuan in the first three quarters, with a year-on-year growth of over 20% [1] - The company reported continued profitability in the third quarter, maintaining a leading position among domestic peers [1] - Operating cash flow for the first three quarters reached 227 million yuan, reflecting a substantial year-on-year increase of 428.78% [1] Product Innovation - The new generation of the transcatheter aortic valve replacement (TAVR) system developed by NVT in Germany received EU CE certification in June 2025 [1] - Global sales of the valve series products surged by 98% year-on-year in the third quarter, achieving a historical high [1] Future Outlook - The company's innovations and international expansion in the cardiovascular field are expected to continue driving growth in the future [1]